Enabling faster, more sustainable biologics manufacturing
CPI is an independent, UK-based technology innovation centre that helps companies develop, prove, and scale up new biopharmaceutical manufacturing processes. With state-of-the-art facilities and deep expertise in biologics, CPI enables organisations to explore process intensification strategies that improve efficiency, sustainability, and cost-effectiveness, without the need for major capital investment.
By leveraging advanced process development platforms such as the Ambr® 250 Perfusion system, alongside digital simulation and modelling tools, CPI supports early-stage process intensification and optimisation. These capabilities create a strong foundation for robust scale-up, increased automation of unit operations, and fully integrated upstream-to-downstream workflows. As an independent innovation partner, CPI offers flexible, open-access support, with no lock-ins to specific cell lines or platforms, giving organisations the freedom to choose the most effective route to successful commercial deployment.
From pressure to progress: The strategic case for process intensification in modern biomanufacturing
Process intensification helps pharma address cost pressures and sustainability goals by delivering higher productivity from smaller, smarter systems. Explore the industry drivers behind intensification and how CPI supports organisations to validate, de-risk and scale digitally enabled biomanufacturing.
DownloadSmarter, smaller, stronger: How process intensification can help pharma overcome cost, scale and sustainability barriers.
Biologics manufacturers face rising cost, space and sustainability pressures. Process intensification offers a practical route to higher productivity from smaller, smarter systems. This blog explores how CPI helps organisations validate intensified processes, reduce COGS and footprint, and build agile, digitally enabled biomanufacturing.
DownloadCase study: Integrating continuous technologies for the rapid, cost-effective delivery of biotherapeutics to patients
Find out how CPI and ndustry partners built a modular, end-to-end continuous biomanufacturing platform, reducing analysis time from eight hours to 30 minutes and powering agile, cost-effective production of biologics.
DownloadCase study: Automated process development of downstream mab purification using novel PAT sensors
Causeway Sensors worked with CPI and Industrial Systems Control on an Innovate UK-funded project, embedding the Titan SPR sensor into CPI’s continuous biomanufacturing rig. The collaboration demonstrated automated, in-line monitoring of monoclonal antibody purification, accelerating technology validation and enabling more efficient biologics manufacturing.
DownloadAccelerating sustainable, intensified pharmaceutical production, with the PHARMECO partnership
PHARMECO is a major public–private partnership accelerating sustainable pharmaceutical manufacturing. Bringing together 31 organisations, it advances intensified, low-impact production. CPI co-leads biologics work on continuous, model-based processes, greener materials and real-time control. The programme targets major reductions in solvents, waste and emissions while developing shared sustainability tools for industry.
DownloadTurn questions into evidence: designed for bioprocessing innovators who need to move fast
Gain data-backed insight into process efficiency, cost and sustainability improvements, without major capital outlay. Work with CPI’s experts to model and validate intensified processes, enabling confident, low-risk manufacturing decisions and a clear conclusion on whether process intensification is right for you.
DownloadExplore your process challenges with CPI’s biologics experts in a free diagnostic workshop
Join CPI’s biologics experts for a free, one-hour diagnostic workshop designed to help you unpack the challenges holding back your upstream or downstream performance. In this focused session, we will explore where productivity losses, scale constraints, or cost pressures are emerging in your process, and discuss how process intensification could help you overcome them. You will leave with clear next steps, practical insight, and a better understanding of whether intensification could deliver meaningful improvements for your organisation.
Contact Asif Tulah at CPI to arrange.Process intensification: your key questions answered
Discover when process intensification is suitable, how it contrasts with continuous processing, and how CPI’s staged approach clarifies performance, economics, scalability, and tech transfer for both legacy and new biologics processes.
DownloadEnabling the development of intensified processes
Discover innovations that intensify mRNA–LNP manufacturing to cut costs and enhance sustainability. The presentation highlights material inefficiencies, reaction optimisation, continuous and integrated processing, immobilised templates, enzyme reuse, and advanced PAT.
DownloadDiscover what’s possible
Book a virtual tour of CPI’s National Biologics Manufacturing Centre to see our state-of-the-art equipment in action, including the Ambr® 250 Perfusion system and cutting-edge digital simulation and modelling tools.
Complete the form to book